Prescription Aripiprazole tablets recalled nationwide for storage temperature deviation
Cardinal Healthcare is recalling Aripiprazole 5 mg tablets nationwide due to CGMP deviations. Products were exposed to temperatures outside labeled storage conditions. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with CGMP storage deviation; no reported illnesses or injuries and no confirmed product harm; the hazard is theoretical rather than confirmed damage.
Plain-English summary
Cardinal Healthcare initiated a nationwide recall of Aripiprazole 5 mg tablets (NDC 65162-897-03, Batch AR202318) distributed by Amneal Pharmaceuticals LLC. The recall was triggered by Current Good Manufacturing Practice (CGMP) deviations discovered during manufacturing quality controls.
The deviation involved exposure of products to temperatures outside the labeled storage conditions. This storage condition deviation occurred during the production process.
No illnesses or injuries have been reported in connection with this recall. Patients currently taking the affected batch should contact their healthcare provider or pharmacist. Do not discontinue use without consulting your healthcare provider first.
Consumers with questions about whether they have affected product should verify the batch number (AR202318) on their prescription bottle. Those with the recalled batch or who experience any adverse effects should report concerns to the FDA MedWatch program or their healthcare provider.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- CARDINAL HEALTHCARE
- Category
- Drug — Antipsychotic
- Hazard
- temperature-excursion
- storage-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch AR202318
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27